TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 4761-4769

  Binsky, Inbal ^a   Lantner, Frida ^a   Grabovsky, Valentin ^a   Harpaz, Nurit ^b   Shvidel, Lev ^b   Berrebi, Alain ^b   Goldenberg, David M ^c   Leng, Lin ^d   Bucala, Richard ^d   Alon, Ronen ^a   Haran, Michal ^b   Shachar, Idit ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; INTEGRIN; PROTEIN P63; TAP63 PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; APOPTOSIS REGULATORY PROTEIN; B LYMPHOCYTE ANTIGEN; BLOCKING ANTIBODY; HLA ANTIGEN CLASS 2; ISOMERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CELL HOMING; CELL INTERACTION; CELL MIGRATION; CELL STIMULATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CELL MOTION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INVARIANT CHAIN; METABOLISM; MIDDLE AGED; MIGRATION INHIBITION; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; CELL MIGRATION INHIBITION; CELL MOVEMENT; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTEGRIN ALPHA4BETA1; INTRAMOLECULAR OXIDOREDUCTASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 77954523022     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0904149     Document Type: Article

References (36)

1. Caligaris-Cappio, F. 1996. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87: 2615-2620.
2. Binet, J. L., M. Lepoprier, G. Dighiero, D. Charron, P. D'Athis, G. Vaugier, H. M. Beral, J. C. Natali, M. Raphael, B. Nizet, and J. Y. Follezou. 1977. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40: 855-864.
3. Gray, J. L., A. Jacobs, and M. Block. 1974. Bone marrow and peripheral blood lymphocytosis in the prognosis of chronic lymphocytic leukemia. Cancer 33: 1169-1178.
4. Binsky, I., M. Haran, D. Starlets, Y. Gore, F. Lantner, N. Harpaz, L. Leng, D. M. Goldenberg, L. Shvidel, A. Berrebi, et al. 2007. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc. Natl. Acad. Sci. U.S.A. 104: 13408-13413.
5. Stumptner-Cuvelette, P., and P. Benaroch. 2002. Multiple roles of the invariant chain in MHC class II function. Biochim. Biophys. Acta 1542: 1-13.
6. Matza, D., A. Kerem, and I. Shachar. 2003. Invariant chain, a chain of command. Trends Immunol. 24: 264-268.
7. Starlets, D., Y. Gore, I. Binsky, M. Haran, N. Harpaz, L. Shvidel, S. Becker-Herman, A. Berrebi, and I. Shachar. 2006. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107: 4807-4816.
8. Gore, Y., D. Starlets, N. Maharshak, S. Becker-Herman, U. Kaneyuki, L. Leng, R. Bucala, and I. Shachar. 2008. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J. Biol. Chem. 283: 2784-2792.
9. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, and R. Bucala. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476.
10. Shi, X., L. Leng, T. Wang, W. Wang, X. Du, J. Li, C. McDonald, Z. Chen, J. W. Murphy, E. Lolis, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606.
11. Stein, R., Z. Qu, T. M. Cardillo, S. Chen, A. Rosario, I. D. Horak, H. J. Hansen, and D. M. Goldenberg. 2004. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104: 3705-3711.
12. Lantner, F., D. Starlets, Y. Gore, L. Flaishon, A. Yamit-Hezi, R. Dikstein, L. Leng, R. Bucala, Y. Machluf, M. Oren, and I. Shachar. 2007. CD74 induces TAp63 expression leading to B-cell survival. Blood 110: 4303-4311.
13. Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dötsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2: 305-316.
14. Yang, A., R. Schweitzer, D. Sun, M. Kaghad, N. Walker, R. T. Bronson, C. Tabin, A. Sharpe, D. Caput, C. Crum, and F. McKeon. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
15. Mills, A. A., B. Zheng, X. J. Wang, H. Vogel, D. R. Roop, and A. Bradley. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
16. Carroll, D. K., J. S. Carroll, C. O. Leong, F. Cheng, M. Brown, A. A. Mills, J. S. Brugge, and L. W. Ellisen. 2006. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat. Cell Biol. 8: 551-561.
17. Haran, M., S. Chebatco, L. Flaishon, F. Lantner, N. Harpaz, L. Valinsky, A. Berrebi, and I. Shachar. 2004. Grb7 expression and cellular migration in chronic lymphocytic leukemia: a comparative study of early and advanced stage disease. Leukemia 18: 1948-1950.
18. Cheson, B. D., J. M. Bennett, M. Grever, N. Kay, M. J. Keating, S. O'Brien, and K. R. Rai. 1996. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997.
19. Hallek, M., B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, and T. J. Kipps. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
20. Stein, R., M. J. Mattes, T. M. Cardillo, H. J. Hansen, C. H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg. 2007. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13: 5556s-5563s.
21. Bernhagen, J., R. A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155.
22. Candi, E., R. Cipollone, P. Rivetti di Val Cervo, S. Gonfloni, G. Melino, and R. Knight. 2008. p63 in epithelial development. Cell. Mol. Life Sci. 65: 3126-3133.
23. Luger, D., M. Dayan, H. Zinger, J. P. Liu, and E. Mozes. 2004. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24: 579-590.
24. Burger, J. A., M. Burger, and T. J. Kipps. 1999. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94: 3658-3667.
25. Warnock, R. A., S. Askari, E. C. Butcher, and U. H. von Andrian. 1998. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J. Exp. Med. 187: 205-216.
26. Dios, A., R. A. Mitchell, B. Aljabari, J. Lubetsky, K. O'Connor, H. Liao, P. D. Senter, K. R. Manogue, E. Lolis, C. Metz, et al. 2002. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45: 2410-2416.
27. Cournia, Z., L. Leng, S. Gandavadi, X. Du, R. Bucala, and W. L. Jorgensen. 2009. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem. 52: 416-424.
28. Hartmann, T. N., V. Grabovsky, W. Wang, P. Desch, G. Rubenzer, S. Wollner, I. Binsky, A. Vallon-Eberhard, A. B. Sapoznikov, M. Burger, et al. 2009. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res. 69: 3121-3130.
29. Sipkins, D. A., X. Wei, J. W. Wu, J. M. Runnels, D. Côté, T. K. Means, A. D. Luster, D. T. Scadden, and C. P. Lin. 2005. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435: 969-973.
30. Cinamon, G., V. Shinder, R. Shamri, and R. Alon. 2004. Chemoattractant signals and beta 2 integrin occupancy at apical endothelial contacts combine with shear stress signals to promote transendothelial neutrophil migration. J. Immunol. 173: 7282-7291.
31. Ghia, P., L. Granziero, M. Chilosi, and F. Caligaris-Cappio. 2002. Chronic B cell malignancies and bone marrow microenvironment. Semin. Cancer Biol. 12: 149-155.
32. Chappell, C. P., and E. A. Clark. 2008. Survival niches: B cells get MIFed as well as BAFFled by dendritic cells. Immunol. Cell Biol. 86: 487-488.
33. Sapoznikov, A., Y. Pewzner-Jung, V. Kalchenko, R. Krauthgamer, I. Shachar, and S. Jung. 2008. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat. Immunol. 9: 388-395.
34. Shanafelt, T. D., S. M. Geyer, N. D. Bone, R. C. Tschumper, T. E. Witzig, G. S. Nowakowski, C. S. Zent, T. G. Call, B. Laplant, G. W. Dewald, et al. 2008. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br. J. Haematol. 140: 537-546.
35. Gattei, V., P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al. 2008. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111: 865-873.
36. Rossi, D., A. Zucchetto, F. M. Rossi, D. Capello, M. Cerri, C. Deambrogi, S. Cresta, S. Rasi, L. De Paoli, C. L. Bodoni, et al. 2008. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 93: 1575-1579.